San Diego, California–(Newsfile Corp. – August 24, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training of psychotherapists for its upcoming Phase 2a clinical trial using synthetic psilocybin in combination with…


Previous articleSame But Different: Antidepressant Mechanisms of Psilocybin and Ketamine
Next articleAwakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan